Gardasil-9 is now approved for men and women aged 27-45 years.
ATLANTA – Postlicensure surveillance shows no new or unexpected adverse events with aIIV3 (FLUAD).
Vaccines will contain a new A (H3N2) component and B antigen. The live attenuated influenza vaccine returns as an option for those 2- to 49-years...
No preferential recommendation is made for one flu vaccine product over another.
MALMO, SWEDEN – High immunogenicity and safety shown in interim analysis of phase 2 trial.